Skip Navigation

European Heart Journal 2003 24(3):219-220; doi:10.1016/S0195-668X(02)00692-9
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Pratt, C.M
Right arrow Articles by Waldo, A.L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pratt, C.M
Right arrow Articles by Waldo, A.L
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

All that glitters is not gold

C.M Pratta,* and A.L Waldob

a Baylor College of Medicine, Houston, Texas, USA
b Case Western Reserve University, Cleveland, Ohio, USA

* Corresponding author
sx151@po.cwrw.edu

The first 10% of the full text of this article appears below.

See doi:10.1016/S1095-668X(02)00427-Xfor the article to which this editorial refers.

Antiarrhythmic drugs as primary therapy for prevention of sudden cardiac death in patients at risk have largely had a disappointing track record.1 This is particularly true for patients with left ventricular dysfunction. And risk stratification that identifies patients most likely to benefit from antiarrhythmic drug therapy is always welcome. So, it is with considerable interest that Brendorp et al.2 offer an analysis of the DIAMOND CHF trial which indicates that patients in the trial whose QTc interval was ≤429ms appear to have had a therapeutic benefit in a trial . . . [Full Text of this Article]

1. Analogies from previous clinical trials

2. Issue of subset analysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Survival after withdrawal of dofetilide in patients with congestive heart failure and a short baseline QTc interval: A follow-up on the Diamond–CHF QT substudy
B Brendorp, C Torp-Pedersen, H Elming, L Køber, and for the DIAMOND study group
EHJ 2003 24: 274-279. [Abstract] [Full Text]